canakinumab
novartis
['nsclc', 'canakinumab', 'canopy-a', 'sclc']
#esmo22: canopy-a trial shows lack of clinical benefit with adjuvant canakinumab in completely resected #nsclc read the daily reporter article to know more 
The European Society for Medical Oncology (ESMO) is the leading organisation for cancer education and information, supporting the oncology community’s work.